4D Molecular Therapeutics | Sustainability Performance
Develops gene therapies for ophthalmic and pulmonary diseases using engineered vectors.
2013
United States
201 - 500 employees
Biotechnology
$25M - 100M in revenue
N/A in profitability
Sustainability Ranking & Industry Benchmark
#7376
Overall#1560
in United States#151
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and exclusionsFinancial Data
Business performanceCapital & innovation
Market cap
Revenue
R&D intensity
Market cap
Revenue
EBITDA
Operating margin
Revenue by region
Revenue by region %
NETHERLANDS
UNITED STATES
Powered by illuminem
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
229.4%FY2025
R&D as % of revenue
R&D as % of revenue
Industry benchmark
Powered by illuminem
Return on invested capital
-27.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
36%
Independent Directors
5 out of 14 incl. management
Overall score
56
Environment
56
Social
92
Governance
21
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
Reporting
Not reporting on Sustainability
Not committed to key sustainability initiatives